Tag: cancer genetics

December 3, 2018 Intelligence: Late Breaking Lab News

By Robert Michel, from the Volume XXV No. 17 – December 3, 2018 issue

Another long-established regional laboratory company is about to be acquired. On November 27, Boyce and Bynum Pathology Laboratories of Columbia, Mo., disclosed that it had entered an agreement to be acquired by Quest Diagnostics Inc. Notably, the press release about the agreement states that the anatomic pathology division, Boyce and Bynum Professional Services, Inc., and the

View Article

June 18, 2018 Intelligence: Late Breaking Lab News

By Robert Michel, from the Volume XXV No. 9 – June 18, 2018 issue

In New Jersey last week, David Nicoll, 44, the former owner of Biodiagnostic Laboratory Services (BLS) of Parsippany, N.J. was sentenced to 72 months in a federal prison. On the same day, his brother, Scott Nicoll, 37, who also worked at BLS, was sentenced to 43 months in prison. Both had previously pled guilty to U.S.

View Article

Issues Encountered with Anthem’s Pre-approval

By Joseph Burns, from the Volume XXIV, No. 11 – August 7, 2017 issue

CEO SUMMARY: Since Anthem and AIM Specialty Health began a prior-authorization program for genetic testing July 1, a Northeast lab has not had any genetic tests approved through the new system. Physicians told the lab that the steps required for prior authorization were disruptive. Those doctors who regularly order genetic tests had not been trained

View Article

Anthem Launches Program to Manage Genetic Tests

By Joseph Burns, from the Volume XXIV, No. 9 – June 26, 2017 issue

CEO SUMMARY: Pre-authorization of genetic tests is coming to physicians serving patients insured by Anthem, Inc. Its specialty benefits management company, AIM Specialty Health, will manage the program. AIM will work with InformedDNA, a company that specializes in genetic testing clinical decision support and genetic counseling for health insurers. Anthem has about 40 million members

View Article

April 28, 2014 Intelligence: Late Breaking Lab News”

By Robert Michel, from the Volume XXI NO. 6 – April 28, 2014 issue

In recent years, a series of decisions involving molecular diagnostics tests made by Medicare officials and the Medicare Administrative Contractors (MACs) have caused much disruption in the clinical laboratory industry. In response to these developments, on April 16, the California Clinical Laboratory Association (CCLA) and a Medicare beneficiary filed a lawsuit against the U.S. Department

View Article

April 15, 2013 “Intelligence: Late Breaking Lab News”

By Robert Michel, from the Volume XX No. 5 - April 15, 2013 issue

Geisinger Health System broke ground last month on construction of a new $52 million medical laboratory facility. It will be 115,000 square feet and will be located at the site of the Geisinger Medical Center in Danville, Pennsylvania.
LAB COMPANY COMPLETES IPO
Cancer Genetics, Inc., of Rutherford, New Jersey, completed an initial public offering (IPO) and

View Article

September 17, 2012 “Intelligence: Late Breaking Lab News”

By Robert Michel, from the Volume XIX No. 13 - September 17, 2012 issue

Exome sequencing testing for cancer patients is now offered by the Cancer Genetics Laboratory at Baylor College of Medicine (BCM) in Houston, Texas. This clinical testing will be performed using next-generation gene sequencing technology. Pathologists at Baylor are among the first in the nation to offer exome-based testing services. “Cancer exome sequencing is poised to

View Article

Exome Sequencing Next “Big Thing” for Diagnosis

By Joseph Burns, from the Volume XIX No. 5 - April 2, 2012 issue

CEO SUMMARY: For disease diagnostics, exome sequencing is not yet routine, but geneticists are getting close. Using this technology, researchers read those parts of the human genome where about 85% of disease-causing mutations reside. By looking only at the regions that encode proteins—the workhorse machinery of the cell—researchers identify dis- ease causes much faster than

View Article

MedTox, Cleveland Clinic Labs, Apollo PACS, Dell, British Columbia Health

By Robert Michel, from the Volume XIX No. 3 - February 20, 2012 issue

GENOME SEQUENCING TO BE OFFERED BY NORWAY IN NATIONAL HEALTH PLAN
HERE’S A MILESTONE ON THE PATH TO PERSONALIZED MEDICINE. Norway is the first nation to announce that its national health system will incorporate whole genome sequencing.

Cancer is the target of Norway’s first genome sequencing program. What sets the Norwegian program apart from gene testing activities

View Article

Review of 2004 Lab Sales Identifies Buyer Interest

By Robert Michel, from the Volume XII No. 3 - February 14, 2005 issue

CEO SUMMARY: Laboratory acquisition activity was surprisingly high during 2004. One reason is that new buyers appeared in the marketplace. However, all buyers have specific acquisition criteria. When a selling lab meets that criteria, it can expect multiple bidders and a strong purchase price. Here’s a review of 2004’s lab acquisition activity, with commentary about

View Article

Volume XXVI No. 2 – February 4, 2019

NOW THAT MOST HOSPITALS ARE INCLUDED as applicable laboratories that must report their PAMA private payer lab test price data to the Centers for Medicare and Medicaid Services, managers of those labs will benefit from the incisive analysis in this issue of the lessons learned during the 2017 PAMA reporting cycle. THE DARK REPORT further offers recommendations on how labs can do a better job of gathering and reporting their own data to CMS. Also, TDR delivers an exclusive analysis of why the Government Accounting Office's assertion that CMS will be paying billions more for Part B clinical lab tests is simply wrong.

See the full table of contents

Tag: cancer genetics

Enter Your Login Credentials